INFY 1,480.20 +8.90 (0.60%) HDFCBANK 1,910.35 -6.00 (-0.31%) NESTLEIND 2,414.20 -20.60 (-0.85%) BHARTIARTL 1,815.60 -29.20 (-1.58%) RELIANCE 1,300.05 -1.60 (-0.12%) DMART 4,373.55 -123.30 (-2.74%) WIPRO 240.80 -1.95 (-0.80%) TCS 3,447.35 +46.10 (1.36%) ICICIBANK 1,404.55 +2.30 (0.16%) ITC 428.15 -1.95 (-0.45%) KOTAKBANK 2,203.00 -21.00 (-0.94%) ONGC 246.35 -3.00 (-1.20%) HINDUNILVR 2,331.60 +6.35 (0.27%) ASIANPAINT 2,430.20 -34.40 (-1.40%) HCLTECH 1,579.30 -7.60 (-0.48%) HDFCLIFE 705.00 -3.20 (-0.45%) MARUTI 11,685.90 -214.90 (-1.81%) LT 3,272.15 -28.40 (-0.86%) ULTRACEMCO 12,236.20 +73.05 (0.60%) BAJAJFINSV 2,045.35 -60.05 (-2.85%) SUNPHARMA 1,786.85 -17.65 (-0.98%) HDFC 2,729.95 -17.05 (-0.62%) BPCL 295.40 -6.55 (-2.17%) AXISBANK 1,165.30 -42.00 (-3.48%) POWERGRID 306.25 -8.05 (-2.56%) TITAN 3,362.15 -22.20 (-0.66%) SBIN 798.75 -14.45 (-1.78%) BAJFINANCE 9,111.20 -186.90 (-2.01%) NTPC 356.30 -6.75 (-1.86%) BRITANNIA 5,419.75 -43.80 (-0.80%)

Download Unicorn Signals App

By EquityPandit

Glenmark Pharma receives USFDA nod for Colesevelam Hydrochloride

July 17, 2018

Glenmark Pharma has received final approval for Colesevelam Hydrochloride, from USFDA.

Colesevelam Hydrochloride is a generic version of Welchol 1 of Daiichi Sankyo Inc and the company has received approval for Colesevelam Hydrochloride for Oral Suspension, 1.875 grams/Packet and 3.75 grams/Packet. Furthermore, the company has completed the formalities for the acquisition of the equity stake and has acquired the 100% equity share holding of Zorg.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week

Latest
IPO

Weekly
Outlook

Stock

Market
Prediction